Karuna Therapeutics, Inc.
(NASDAQ : KRTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.68%145.650.7%$932.14m
PFEPfizer Inc. 0.84%36.060.9%$892.16m
MRKMerck & Co., Inc. -0.24%82.950.7%$692.55m
ABBVAbbVie, Inc. 0.35%86.211.9%$677.02m
BMYBristol-Myers Squibb Co. 2.15%59.501.0%$637.89m
LLYEli Lilly & Co. 0.97%150.261.1%$561.78m
AZNAstraZeneca Plc 2.47%55.511.2%$257.73m
NVSNovartis AG 0.96%87.130.2%$163.92m
GSKGlaxoSmithKline Plc 1.12%37.800.2%$109.18m
PRNBPrincipia Biopharma, Inc. 0.10%100.050.0%$86.76m
NVONovo Nordisk A/S 1.13%69.040.1%$57.64m
RGENRepligen Corp. 3.12%144.307.1%$49.54m
SNYSanofi -0.02%50.780.2%$49.00m
RPRXRoyalty Pharma Plc -0.40%40.070.2%$47.01m
OPKOPKO Health, Inc. 4.89%3.2211.2%$43.56m

Company Profile

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders.The company was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.